Locate providers:   

Cynosure Continues to Expand the Smartlipo(TM) LaserBodySculpting Product Family


New 18-Watt System Launched at Plastic Surgery 2007 Meeting

WESTFORD, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced the addition of an 18-watt workstation to its family of Smartlipo LaserBodySculpting(SM) products. This higher-power workstation will allow physicians to continue to reduce patient treatment times for laser-assisted liposuction. Cynosure is introducing the 18-watt Smartlipo at the American Society of Plastic Surgeons (ASPS) meeting, Plastic Surgery 2007, which is continuing through October 31 at the Baltimore Convention Center.

In addition to its new 18-watt system, Cynosure (booth #906) offers Smartlipo in upgradeable configurations of 6-watt and 10-watt workstations, each designed to address the specific needs of an aesthetic practice. All systems in the field can be upgraded to the new 18-watt system.

"The 18-watt Smartlipo workstation provides practitioners a highly efficient approach for performing laser-assisted liposuction, with the same level of safety and efficacy as earlier versions," said Bruce Katz, M.D., founder of New York's Juva Skin & Laser Center. "For example, an area of localized fat within an abdomen can be treated in about 12 minutes with the 18-watt Smartlipo, compared with about 35 minutes with the 6-watt workstation."

Launched in January, Cynosure's minimally invasive Smartlipo workstation is an innovative system designed as an alternative to traditional liposuction in patients with smaller areas of localized fat. The system's proprietary pulsing format delivers laser energy that liquefies the fat, which is then removed through a cannula. The Smartlipo's laser energy also coagulates the tissue, thereby sculpting body contours and tightening the skin. The procedure generally causes less bleeding, swelling and bruising than traditional liposuction, resulting in fewer complications and faster recovery. Cynosure received U.S. Food and Drug Administration clearance to market Smartlipo in the fourth quarter of 2006.

"The addition of the more powerful 18-watt system to our Smartlipo product family is designed to benefit physicians, such as plastic surgeons and dermatologists, who are experienced in body sculpting," said Cynosure President and Chief Executive Officer Michael Davin. "The minimally invasive nature of the Smartlipo makes it an increasingly attractive option for active patients who want to remove localized areas of fat through a procedure that keeps lifestyle disruption to a minimum. As a result, we believe Smartlipo is enjoying a high level of satisfaction from physicians and patients."

In conjunction with its launch of the new 18-watt Smartlipo system, Cynosure is hosting The Laser Assisted Liposuction Symposium during Plastic Surgery 2007. Moderated by Dr. Barry DiBernardo, medical director of New Jersey Plastic Surgery, the symposium will feature a panel discussion on areas including the history and science of laser lipolysis, clinical indications and patient outcomes.

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd: YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991.

For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosure.com.

Safe Harbor

Any statements in this press release about future expectations, plans and prospects for Cynosure's 18-watt Smartlipo LaserBodySculpting(SM) system constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements contain the words "believes," "anticipates," "plans," "expects," "will" and similar expressions. Actual results may differ materially from those indicated by such forward- looking statements as a result of various important factors, including Cynosure's history of operating losses, its reliance on sole source suppliers, the inability to accurately predict the success of the 18-watt Smartlipo workstation, changes in consumer preferences, competition in the aesthetic laser industry as well economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.

SOURCE Cynosure, Inc.

CONTACT: Scott Solomon, Vice President of Sharon Merrill Associates, Inc., +1-617-542-5300, cyno@investorrelations.com, for Cynosure, Inc. Web site: http://www.cynosure.com